Research Peptide Fundamentals: What the Literature Says

The short version

This desk — aminopeptides.net — collects what the peer-reviewed literature says about three compounds that sit at the intersection of metabolic research and cellular aging: semaglutide, MOTS-c, and NAD+. They are not the same kind of thing. Semaglutide is an FDA-approved prescription medicine, a peptide that mimics a hormone called GLP-1 to regulate blood sugar and weight. MOTS-c is a mitochondrial-derived peptide — a tiny signaling molecule encoded not by the DNA in your cell's nucleus but by the ancient genetic code inside your mitochondria. NAD+ is a coenzyme, not a peptide at all, but a small molecule that every cell depends on to generate energy and that declines measurably with age.

What connects them is the question: what happens to metabolic and cellular function as we age, and what does the research say about compounds that might influence it? This site answers that question with citations, not claims. It does not sell anything, does not recommend doses, and does not give medical advice. Where the evidence is solid, it says so; where it is thin, early, or rodent-only, it says that too.

What this desk covers

Each compound on this desk gets its own page tracing the same path:

• Semaglutide — The most clinically validated compound here. A 31-amino-acid GLP-1 receptor agonist with FDA approval across multiple indications, including type 2 diabetes, weight management, and now cardiovascular-risk reduction. This desk covers its mechanism, the major trials (STEP, SELECT, FLOW), and the real safety considerations the literature documents.
• MOTS-c — The lead compound on this desk and the most scientifically unusual: a peptide whose gene lives inside your mitochondria, not your chromosomes. Animal data suggest it improves insulin sensitivity and physical performance by activating AMPK via the folate cycle. Human data are observational biomarker work so far — this desk is honest about that gap.
• NAD+ — Not a peptide but central to the cellular-aging story. NAD+ declines with age, and the enzymes that use it — sirtuins, PARPs, CD38 — govern some of the most-studied longevity pathways. Human trials with precursors like NMN and NR have raised blood NAD+ reliably; translation to clinical endpoints is still an open question.

For a side-by-side view, see the comparison page.

The metabolic and cellular-aging frame

All three compounds on this desk have been studied because of how they interact with metabolic function and the biology of aging cells.

The current model of cellular aging emphasizes that mitochondria become less efficient, NAD+ stores fall, DNA-repair enzymes slow, and metabolic signaling grows noisier. Semaglutide targets some of those signals directly — pancreatic beta-cell function, appetite circuits in the brain, and, through weight-loss effects, downstream cardiovascular outcomes ^[3][4]. MOTS-c is, in a sense, a product of mitochondrial stress-sensing itself: it rises in the blood after exercise and in response to metabolic challenge, where it feeds into AMPK — the cell's low-fuel alarm — to correct glucose uptake and reduce insulin resistance ^[11]. NAD+ is upstream of much of this: without adequate NAD+, neither the sirtuins that regulate stress-response gene expression nor the PARPs that patch DNA breaks work at full capacity ^[16].

Seen together, they frame a single set of questions about cellular metabolism and aging from three different entry points.

What are research peptides?

A peptide is a short chain of amino acids — the same building blocks that make proteins, only fewer of them. Semaglutide, for example, is 31 amino acids long; MOTS-c is 16. Proteins can be hundreds or thousands of amino acids, folded into complex shapes. Peptides are small enough that they can sometimes act like molecular keys, fitting receptors on cell surfaces and switching specific processes on or off.

"Research peptide" is the term used for peptides that have been synthesized and studied in the laboratory but not approved as medicines — or not yet, or not for the indication being studied. MOTS-c is firmly in this category: no human clinical trials, research-chemical status only. Semaglutide, by contrast, has crossed into approved medicine territory for several indications. NAD+ occupies a third lane: it is not a peptide, and it is sold as a dietary supplement, though its precursors (NMN, NR) have faced regulatory uncertainty.

This desk tracks where each compound sits in that spectrum — approved, investigational, supplement, or research-only — so the status is always visible in context.